VIDEO: Ixo-vec gene therapy shows safe results throughout 4-year study period

ORLANDO — In this video from the American Academy of Ophthalmology meeting, Michael W. Stewart, MD, professor and chairman of ophthalmology at the Mayo Clinic, talks about findings from the phase 2 LUNA trial. Stewart told Healio that Ixo-vec (ixoberogene soroparvovec, Adverum Biotechnologies) in neovascular age-related macular degeneration “showed excellent safety signals” throughout the 4-year